[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fresh-embryo-transfer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fresh-embryo-transfer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100639714","gnrh-for-luteal-support---mechanism-of-action-100639714",false,"NCT07620067","GnRH for Luteal Support - Mechanism of Action","Gonadotropin-Releasing Hormone Agonist as a Single Luteal Support - What is Its Mechanism of Action?","Inclusion Criteria:\n\n* Women included in the study will be 18-45 years old\n* undergoing IVF treatments due to ovulation disorder, mechanical factor, primary ovarian insufficiency, or male infertility.\n* All women will be at their first to the third cycle of treatment\n* women will undergo a fresh ET.\n\nExclusion Criteria:\n\n* repeated implantation failure (more than 3 cycles of good quality ET without implantation)\n* moderate-severe endometriosis\n* hydrosalpinx\n* fibroid uterus\n* BMI more than 35 or less than 19\n* women with hypogonadotropic hypogonadism\n* PGT of embryos\n* use of surgical techniques for sperm retrieval\n* preference of the long GnRH-agonist protocol\n* women with rhinitis or nasal congestion.",true,"FEMALE","18 Years","45 Years",{"count":21,"type":22},150,"ESTIMATED","9 Months","OBSERVATIONAL","This prospective observational study will include women undergoing IVF treatment with a GnRH antagonist protocol and fresh embryo transfer at the IVF unit of Shaare Zedek Medical Center. Patients will undergo controlled ovarian stimulation followed by ovulation triggering with hCG, GnRH agonist, or dual trigger according to OHSS risk. After oocyte retrieval and fertilization by IVF\u002FICSI, embryos will be cultured and transferred. Luteal phase support will consist of either intranasal GnRH agonist (Synarel) or vaginal progesterone. Blood and follicular fluid samples will be collected at predefined time points to assess hormonal, inflammatory, and angiogenic markers, including LH, FSH, estradiol, progesterone, IL-6, IL-8, VEGF, PEDF, and relaxin.",[27,28,29],"GnRH Antagonist IVF Protocol","Fresh Embryo Transfer","Administration of Hormonal Luteal Support",[31,32,33,34],"GnRH antagonist","luteal support","mechanism of action","progesterone","RECRUITING","2026-05-26",{"date":38,"type":39},"2026-06-02","ACTUAL",{"date":41,"type":39},"2026-05-18",{"date":43,"type":22},"2026-12-31",{"name":45,"class":46},"Heli Alexandroni","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":47},"100607220","phase-4-ketorolac-use-and-fresh-embryo-transfer-outcomes-100607220","NCT07185724","Ketorolac Use and Fresh Embryo Transfer Outcomes","Balancing Comfort and Success: Post-retrieval Ketorolac in Fresh Embryo Transfers","Inclusion Criteria:\n\n* IVF utilizing autologous oocytes and all sperm sources\n* IVF cycles utilizing ICSI and standard insemination\n* Plan to transfer embryo on day 5\n* BMI below 50\n\nExclusion Criteria:\n\n-allergies or medical contraindications to NSAIDs","37 Years",{"count":57,"type":22},200,"INTERVENTIONAL",[60],"PHASE4","Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy.\n\nHowever, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle).\n\nDespite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research.\n\nThis study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would.\n\nPrimary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia.\n\nSecondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w\u002Fin 24 hours for pain\u002Fbleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.",[63,64,65,28,66],"Infertility (IVF Patients)","Infertility Treatment","Post-op Pain","Oocyte Retrieval and Post Operative Pain Control",[68,69,70,71,72,73,74,75,76],"IVF","post operative pain control","oocyte retrieval","fresh embryo transfer","ketorolac","toradol","implantation rate","live birth rate","miscarriage rate","2025-12-11",{"date":79,"type":39},"2025-12-15",{"date":81,"type":39},"2025-11-08",{"date":83,"type":22},"2028-09-01",{"name":85,"class":46},"Jessica D. Kresowik",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":58,"phases":97,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":47},"100606162","ivm---fresh-et-the-saigon-protocol-versus-ivf---fet-in-pcos-women-100606162","NCT07171970","IVM - Fresh ET (THE SAIGON PROTOCOL) Versus IVF - FET in PCOS Women","The Effectiveness and Safety of In Vitro Maturation With Fresh Embryo Transfer (The SAIGON Protocol) Versus In Vitro Fertilization With Frozen Embryo Transfer in Women With Polycystic Ovary Syndrome","SAIGON-PTC","Inclusion Criteria:\n\n* Women aged 18 - 42 years old.\n* Diagnosed with PCOS, followed Rotterdam 2003 criteria (Group TREP consensus workshop, 2004)\n* Had fewer than three previous failed frozen embryo transfer (FET) cycles\n* Transferred no more than two cleavage embryos or one good-quality blastocyst or no more than two poor-quality blastocysts.\n* Agreeing to participate in the study\n\nExclusion Criteria:\n\n* Having allergy and contraindications for exogenous hormone administration (e.g., breast cancer, thromboembolic disease)\n* Cycles with preimplantation genetic testing indication\n* Oocyte donation cycles\n* Having untreated uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus, large leiomyoma ≥5 cm in diameter; adenomyosis, endometrial polyp, hydrosalpinx).","42 Years",{"count":96,"type":22},600,[98],"NA","Assisted Reproductive Technologies (ART) aim to increase success rates while minimizing patient risks. For women with high AFC or PCOS, conventional IVF carries a high risk of OHSS (Ho et al., 2019). A modern IVF strategy to prevent this uses a GnRH agonist trigger, requiring a \"freeze-all\" and subsequent FET (Wong et al., 2017). This reduces OHSS risk but can increase time to pregnancy (Vuong et al., 2021) and treatment burden.\n\nIVM is a patient-friendly alternative that eliminates OHSS risk by avoiding high-dose gonadotropins. A 2020 trial by Vuong et al. compared CAPA-IVM-FET to conventional IVF-FET in women with high AFC. IVM yielded a comparable live birth rate (35.2%) versus IVF (43.2%), with a 0% OHSS rate in IVM compared to 0.7% in IVF (Vuong et al., 2020).\n\nThe optimal transfer method (fresh or frozen) in IVM cycles is debated. A 2021 pilot RCT by Vuong et al. found a freeze-only strategy after CAPA-IVM led to a significantly higher live birth rate (60%) than a fresh transfer (20%) (Vuong et al., 2021), but increased time to pregnancy (194 vs. 150 days) (Vuong et al., 2021). A refined CAPA-IVM protocol, which uses no gonadotropins, allowed for fresh embryo transfer in the same cycle, resulting in a numerically higher ongoing pregnancy rate (43.3% vs. 33.3%) than FET (Vuong et al., 2025).\n\nThis raises an important question: how does a simplified IVM strategy with fresh transfer compare to the established \"safety-net\" IVF strategy with FET? These two approaches represent opposing clinical philosophies. No large-scale study has yet compared them in women with PCOS. Therefore, this study is designed to compare the SAIGON protocol (gonadotropin-free CAPA-IVM with fresh ET) against a standard GnRH-antagonist IVF protocol with agonist trigger and subsequent FET.",[101,102,28],"Polycystic Ovary Syndrome (PCOS)","In Vitro Maturation of Oocytes",[104,105,71,106,107],"in vitro maturation","The SAIGON protocol","GnRH-Antagonist","frozen embryo transfer","2025-09-30",{"date":110,"type":39},"2025-10-01",{"date":112,"type":39},"2025-09-22",{"date":114,"type":22},"2028-01-15",{"name":116,"class":46},"Mỹ Đức Hospital"]